Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs

Schizophrenia Research

Volumn 125, Issue 2-3, 2011, Pages 187-193

  Moons, Tim ^a   Claes, Stephan ^b   Martens, Gerard J M ^b   Peuskens, Joseph ^a   Van Loo, Karen M J ^b   Van Schijndel, Jessica E ^b   De Hert, Marc ^a   van Winkel, Ruud ^a,c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; LEPTIN RECEPTOR; MELANOCORTIN 3 RECEPTOR; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PER2 PROTEIN; QUETIAPINE; RISPERIDONE; STEROID RECEPTOR COACTIVATOR 3; SYNDECAN 3; TRANSCRIPTION FACTOR CLOCK;

ALLELE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; CIRCADIAN RHYTHM; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WILD TYPE;

ADULT; AGE FACTORS; ALLELES; ANTHROPOMETRY; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY COMPOSITION; BODY MASS INDEX; CLOCK PROTEINS; CLOZAPINE; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HETEROZYGOTE DETECTION; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; MUTATION, MISSENSE; PERIOD CIRCADIAN PROTEINS; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOTIC DISORDERS; QUINOLONES; RECEPTOR, MELANOCORTIN, TYPE 3; RECEPTORS, GLUCOCORTICOID; RECEPTORS, LEPTIN; RISPERIDONE; SCHIZOPHRENIA; SEX FACTORS; SULPIRIDE; SYNDECAN-3;

EID: 78951488004     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.10.008     Document Type: Article

References (62)

1. Beebe K.L., Block T., Debattista C., Blasey C., Belanoff J.K. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Behav. Brain Res. 2006, 171:225-229.
2. Belanoff J.K., Blasey C.M., Clark R.D., Roe R.L. Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain. Diab. Obes. Metab. 2010, 12:545-547.
3. Cleves M. Hardy-Weinberg equilibrium tests and allele frequency estimation. STATA Tech. Bull. 1999, 34-37.
4. Correll C.U. Balancing efficacy and safety in treatment with antipsychotics. CNS Spectr. 2007, 12(12-20):35.
5. De Hert M., Dekker J.M., Wood D., Kahl K.G., Holt R.I., Moller H.J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur. Psychiatry 2009, 24(6):412-424.
6. De Hert M., Schreurs V., Vancampfort D., van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009, 8:15-22.
7. De Hert M., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., Peuskens J. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr. Res. 2006, 83:87-93.
8. de Luis D.A., Gonzalez S.M., Aller R., Izaola O., Conde R. Influence of Lys656Asn polymorphism of leptin receptor gene on insulin resistance in patients with diabetes mellitus type 2. Diab. Res. Clin. Pract. 2008, 81:e9-e11.
9. de Luis R.D., de la Fuente R.A., Sagrado M.G., Izaola O., Vicente R.C. Leptin receptor Lys656Asn polymorphism is associated with decreased leptin response and weight loss secondary to a lifestyle modification in obese patients. Arch. Med. Res. 2006, 37:854-859.
10. Englund A., Kovanen L., Saarikoski S.T., Haukka J., Reunanen A., Aromaa A., Lonnqvist J., Partonen T. NPAS2 and PER2 are linked to risk factors of the metabolic syndrome. J Circadian Rhythms. 2009, 7:5.
11. Fairbrother U.L., Tanko L.B., Walley A.J., Christiansen C., Froguel P., Blakemore A.I. Leptin receptor genotype at Gln223Arg is associated with body composition, BMD, and vertebral fracture in postmenopausal Danish women. J. Bone Miner. Res. 2007, 22:544-550.
12. Feng N., Young S.F., Aguilera G., Puricelli E., Adler-Wailes D.C., Sebring N.G., Yanovski J.A. Co-occurrence of two partially inactivating polymorphisms of MC3R is associated with pediatric-onset obesity. Diabetes 2005, 54:2663-2667.
13. Froy O. Metabolism and circadian rhythms-implications for obesity. Endocr. Rev. 2010, 31:1-24.
14. Garaulet M., Corbalan-Tutau M.D., Madrid J.A., Baraza J.C., Parnell L.D., Lee Y.C., Ordovas J.M. PERIOD2 variants are associated with abdominal obesity, psycho-behavioral factors, and attrition in the dietary treatment of obesity. J. Am. Diet. Assoc. 2010, 110:917-921.
15. Ha E., Kim M.J., Choi B.K., Rho J.J., Oh D.J., Rho T.H., Kim K.H., Lee H.J., Shin D.H., Yim S.V., Baik H.H., Chung J.H., Kim J.W. Positive association of obesity with single nucleotide polymorphisms of syndecan 3 in the Korean population. J. Clin. Endocrinol. Metab. 2006, 91:5095-5099.
16. Heo M., Leibel R.L., Fontaine K.R., Boyer B.B., Chung W.K., Koulu M., Karvonen M.K., Pesonen U., Rissanen A., Laakso M., Uusitupa M.I., Chagnon Y., Bouchard C., Donohoue P.A., Burns T.L., Shuldiner A.R., Silver K., Andersen R.E., Pedersen O., Echwald S., Sorensen T.I., Behn P., Permutt M.A., Jacobs K.B., Elston R.C., Hoffman D.J., Gropp E., Allison D.B. A meta-analytic investigation of linkage and association of common leptin receptor (LEPR) polymorphisms with body mass index and waist circumference. Int. J. Obes. Relat. Metab. Disord. 2002, 26:640-646.
17. Horikawa K., Yokota S., Fuji K., Akiyama M., Moriya T., Okamura H., Shibata S. Nonphotic entrainment by 5-HT1A/7 receptor agonists accompanied by reduced Per1 and Per2 mRNA levels in the suprachiasmatic nuclei. J. Neurosci. 2000, 20:5867-5873.
18. Kishi T., Kitajima T., Ikeda M., Yamanouchi Y., Kinoshita Y., Kawashima K., Okochi T., Okumura T., Tsunoka T., Inada T., Ozaki N., Iwata N. Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:293-297.
19. Kohsaka A., Bass J. A sense of time: how molecular clocks organize metabolism. Trends Endocrinol. Metab. 2007, 18:4-11.
20. Kuningas M., Mooijaart S.P., Slagboom P.E., Westendorp R.G., van H.D. Genetic variants in the glucocorticoid receptor gene (NR3C1) and cardiovascular disease risk. The Leiden 85-plus Study. Biogerontology 2006, 7:231-238.
21. Laika B., Leucht S., Heres S., Schneider H., Steimer W. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J. 2010, 10:20-29.
22. Lee Y.S., Poh L.K., Kek B.L., Loke K.Y. The role of melanocortin 3 receptor gene in childhood obesity. Diabetes 2007, 56:2622-2630.
23. Liu Y.J., Rocha-Sanchez S.M., Liu P.Y., Long J.R., Lu Y., Elze L., Recker R.R., Deng H.W. Tests of linkage and/or association of the LEPR gene polymorphisms with obesity phenotypes in Caucasian nuclear families. Physiol. Genomics 2004, 17:101-106.
24. Manenschijn L., van den Akker E.L., Lamberts S.W., van Rossum E.F. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann. NY Acad. Sci. 2009, 1179:179-198.
25. Mansour H.A., Wood J., Logue T., Chowdari K.V., Dayal M., Kupfer D.J., Monk T.H., Devlin B., Nimgaonkar V.L. Association study of eight circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia. Genes Brain Behav. 2006, 5:150-157.
26. Marcheva B., Ramsey K.M., Affinati A., Bass J. Clock genes and metabolic disease. J. Appl. Physiol. 2009, 107:1638-1646.
27. Marti A., Ochoa M.C., Sanchez-Villegas A., Martinez J.A., Martinez-Gonzalez M.A., Hebebrand J., Hinney A., Vedder H. Meta-analysis on the effect of the N363S polymorphism of the glucocorticoid receptor gene (GRL) on human obesity. BMC Med. Genet. 2006, 7:50.
28. Marti A., Santos J.L., Gratacos M., Moreno-Aliaga M.J., Maiz A., Martinez J.A., Estivill X. Association between leptin receptor (LEPR) and brain-derived neurotrophic factor (BDNF) gene variants and obesity: a case-control study. Nutr. Neurosci. 2009, 12:183-188.
29. Masuo K., Straznicky N.E., Lambert G.W., Katsuya T., Sugimoto K., Rakugi H., Socratous F., Hastings J., Lambert E.A., Ogihara T., Esler M.D. Leptin-receptor polymorphisms relate to obesity through blunted leptin-mediated sympathetic nerve activation in a Caucasian male population. Hypertens. Res. 2008, 31:1093-1100.
30. Maury E., Ramsey K.M., Bass J. Circadian rhythms and metabolic syndrome: from experimental genetics to human disease. Circ. Res. 2010, 106:447-462.
31. Meyer J.M., Stahl S.M. The metabolic syndrome and schizophrenia. Acta Psychiatr. Scand. 2009, 119:4-14.
32. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. J. Clin. Psychiatry 2007, 68(Suppl 4):8-13.
33. Obregon A.M., Amador P., Valladares M., Weisstaub G., Burrows R., Santos J.L. Melanocortin-3 receptor gene variants: association with childhood obesity and eating behavior in Chilean families. Nutrition 2010, 26:760-765.
34. Phillips C.M., Goumidi L., Bertrais S., Field M.R., Ordovas J.M., Cupples L.A., Defoort C., Lovegrove J.A., Drevon C.A., Blaak E.E., Gibney M.J., Kiec-Wilk B., Karlstrom B., Lopez-Miranda J., McManus R., Hercberg S., Lairon D., Planells R., Roche H.M. Leptin receptor polymorphisms interact with polyunsaturated fatty acids to augment risk of insulin resistance and metabolic syndrome in adults. J. Nutr. 2010, 140:238-244.
35. Purcell, S. PLINK v1.07. http://pngu.mgh.harvard.edu/~purcell/plink/.
36. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
37. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
38. Reizes O., Benoit S.C., Strader A.D., Clegg D.J., Akunuru S., Seeley R.J. Syndecan-3 modulates food intake by interacting with the melanocortin/AgRP pathway. Ann. NY Acad. Sci. 2003, 994:66-73.
39. Reynolds G.P., Kirk S.L. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol. Ther. 2010, 125:169-179.
40. Schuring A.N., Lutz F., Tuttelmann F., Gromoll J., Kiesel L., Gotte M. Role of syndecan-3 polymorphisms in obesity and female hyperandrogenism. J. Mol. Med. 2009, 87:1241-1250.
41. Shi J., Levinson D.F., Duan J., Sanders A.R., Zheng Y., Pe'er I., Dudbridge F., Holmans P.A., Whittemore A.S., Mowry B.J., Olincy A., Amin F., Cloninger C.R., Silverman J.M., Buccola N.G., Byerley W.F., Black D.W., Crowe R.R., Oksenberg J.R., Mirel D.B., Kendler K.S., Freedman R., Gejman P.V. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460:753-757.
42. Sookoian S., Gemma C., Gianotti T.F., Burgueno A., Castano G., Pirola C.J. Genetic variants of clock transcription factor are associated with individual susceptibility to obesity. Am. J. Clin. Nutr. 2008, 87:1606-1615.
43. Stahl S.M., Mignon L., Meyer J.M. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?. Acta Psychiatr. Scand. 2009, 119:171-179.
44. StataCorp Stata/SE statistical software, release 11 2009.
45. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., Werge T., Pietilainen O.P., Mors O., Mortensen P.B., Sigurdsson E., Gustafsson O., Nyegaard M., Tuulio-Henriksson A., Ingason A., Hansen T., Suvisaari J., Lonnqvist J., Paunio T., Borglum A.D., Hartmann A., Fink-Jensen A., Nordentoft M., Hougaard D., Norgaard-Pedersen B., Bottcher Y., Olesen J., Breuer R., Moller H.J., Giegling I., Rasmussen H.B., Timm S., Mattheisen M., Bitter I., Rethelyi J.M., Magnusdottir B.B., Sigmundsson T., Olason P., Masson G., Gulcher J.R., Haraldsson M., Fossdal R., Thorgeirsson T.E., Thorsteinsdottir U., Ruggeri M., Tosato S., Franke B., Strengman E., Kiemeney L.A., Melle I., Djurovic S., Abramova L., Kaleda V., Sanjuan J., de F.R., Bramon E., Vassos E., Fraser G., Ettinger U., Picchioni M., Walker N., Toulopoulou T., Need A.C., Ge D., Yoon J.L., Shianna K.V., Freimer N.B., Cantor R.M., Murray R., Kong A., Golimbet V., Carracedo A., Arango C., Costas J., Jonsson E.G., Terenius L., Agartz I., Petursson H., Nothen M.M., Rietschel M., Matthews P.M., Muglia P., Peltonen L., St C.D., Goldstein D.B., Stefansson K., Collier D.A. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
46. Sutton G.M., Begriche K., Kumar K.G., Gimble J.M., Perez-Tilve D., Nogueiras R., McMillan R.P., Hulver M.W., Tschop M.H., Butler A.A. Central nervous system melanocortin-3 receptors are required for synchronizing metabolism during entrainment to restricted feeding during the light cycle. FASEB J. 2010, 24:862-872.
47. Syed A.A., Halpin C.G., Irving J.A., Unwin N.C., White M., Bhopal R.S., Redfern C.P., Weaver J.U. A common intron 2 polymorphism of the glucocorticoid receptor gene is associated with insulin resistance in men. Clin Endocrinol Oxf. 2008, 68:879-884.
48. Takao T., Tachikawa H., Kawanishi Y., Mizukami K., Asada T. CLOCK gene T3111C polymorphism is associated with Japanese schizophrenics: a preliminary study. Eur. Neuropsychopharmacol. 2007, 17:273-276.
49. The International HapMap Project The International HapMap Project. Nature 2003, 426:789-796.
50. van Raalte D.H., Ouwens D.M., Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?. Eur J Clin Invest. 2009, 39:81-93.
51. van Rossum E.F., Koper J.W., Huizenga N.A., Uitterlinden A.G., Janssen J.A., Brinkmann A.O., Grobbee D.E., de Jong F.H., van Duyn C.M., Pols H.A., Lamberts S.W. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 2002, 51:3128-3134.
52. van Rossum E.F., Lamberts S.W. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog. Horm. Res. 2004, 59:333-357.
53. van Schijndel J.E., van Loo K.M., van Z.M., Djurovic S., Andreassen O.A., Hansen T., Werge T., Kallunki P., Pedersen J.T., Martens G.J. Three-cohort targeted gene screening reveals a non-synonymous TRKA polymorphism associated with schizophrenia. J. Psychiatr. Res. 2009, 43:1195-1199.
54. van Winkel R., De Hert M., Van Eyck D., Hanssens L., Wampers M., Scheen A., Peuskens J. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J. Clin. Psychiatry 2006, 67:1493-1500.
55. van Winkel R., De Hert M., Wampers M., Van Eyck D., Hanssens L., Scheen A., Peuskens J. Major changes in glucose metabolism, including new-onset diabetes, within 3months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 2008, 69:472-479.
56. van Winkel R., Moons T., Peerbooms O., Rutten B., Peuskens J., Claes S., van Os J., De Hert M. MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study. Int. Clin. Psychopharmacol. 2010, 25:270-276.
57. van Winkel R., Rutten B., Peerbooms O., Peuskens J., van Os J., De Hert M. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr. Res. 2010, 121:193-198.
58. van Winkel R., van Os J., Celic I., Van E.D., Wampers M., Scheen A., Peuskens J., De Hert M. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J. Clin. Psychiatry 2008, 69:1319-1327.
59. Varcoe T.J., Kennaway D.J., Voultsios A. Activation of 5-HT2C receptors acutely induces Per gene expression in the rat suprachiasmatic nucleus at night. Brain Res. Mol. Brain Res. 2003, 119:192-200.
60. Waddington L.E., Coutu D.L., Cermakian N., Boivin D.B. Circadian rhythms and clock genes in psychotic disorders. Isr. J. Psychiatry Relat. Sci. 2010, 47:27-35.
61. Yang S., Liu A., Weidenhammer A., Cooksey R.C., McClain D., Kim M.K., Aguilera G., Abel E.D., Chung J.H. The role of mPer2 clock gene in glucocorticoid and feeding rhythms. Endocrinology 2009, 150:2153-2160.
62. Zhang J., Liao G., Liu C., Sun L., Liu Y., Wang Y., Jiang Z., Wang Z. The association of CLOCK gene T3111C polymorphism and hPER3 gene 54-nucleotide repeat polymorphism with Chinese Han people schizophrenics. Mol. Biol. Rep. 2010, Epub ahead of print.